Streetbeat News

Stock Prices

LCTX

Lineage Cell Therapeutics (LCTX) is set to release its quarterly earnings report on November 9, 2023. Analysts estimate an earnings per share (EPS) of $-0.04. The company's past performance shows a pattern of beating EPS estimates, which has led to share price increases. However, the stock has been down 18.05% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 4:01 pm

MQ

Marqeta reported better-than-expected Q3 revenue results, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 4:01 pm

TCON

TRACON Pharma (NASDAQ:TCON) is set to release its latest quarterly earnings report on November 9, 2023. Analysts estimate an earnings per share (EPS) of $-0.10. The company's past performance shows a trend of beating EPS estimates but experiencing a drop in share price the following day. The stock is currently trading at $0.15, down 89.97% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 4:01 pm

PHUN

Phunware (NASDAQ:PHUN) is set to release its latest quarterly earnings report on November 9, 2023. Analysts estimate an earnings per share (EPS) of $-0.05. The company's past performance shows a pattern of share price drops following earnings reports. The stock is currently trading at $0.1838, down 86.09% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 4:01 pm

CANO

Cano Health (NYSE:CANO) is set to release its latest quarterly earnings report on November 9, 2023. Analysts estimate an earnings per share (EPS) of $-0.20. The company's previous quarter saw a miss in EPS by $0.39, leading to a 73.0% drop in share price. Over the last 52-week period, shares are down 95.08%.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 4:01 pm

ADPT

Adaptive Biotechnologies (NASDAQ:ADPT) is set to release its quarterly earnings report on November 9, 2023. Analysts estimate an EPS of $-0.34. The company's past performance shows a pattern of share price drops following earnings reports. The stock is currently trading at $4.82, down 49.89% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 4:01 pm

TARS

Tarsus Pharmaceuticals (NASDAQ:TARS) is set to release its latest quarterly earnings report on November 9, 2023. Analysts estimate an earnings per share (EPS) of $-1.36. The company's stock price often reacts to its earnings guidance. Last quarter, TARS missed EPS by $0.09, resulting in a 1.12% drop in share price. The company's shares were trading at $16.07 as of November 7, with a 52-week return of -9.6%.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 4:01 pm

OMER

Omeros (NASDAQ:OMER) is set to release its latest quarterly earnings report on November 9, 2023. Analysts estimate an earnings per share (EPS) of $-0.63. The company's past performance shows a pattern of EPS misses and subsequent share price drops. The stock is currently trading at $1.42, down 50.47% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 4:01 pm

DXPE

DXP Enterprises (NASDAQ:DXPE) is set to release its latest quarterly earnings report on November 9, 2023. Analysts estimate an earnings per share (EPS) of $0.96. The company's previous quarter saw a miss in EPS by $0.03, resulting in a 15.04% drop in share price. The company's shares were trading at $33.65 as of November 7, with a 52-week increase of 22.15%.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 4:00 pm

JELD

In the last quarter, JELD-WEN Holding (NYSE:JELD) received indifferent ratings from four analysts. The average price target is $15.0, compared to the current price of $14.5, implying an upside. This average has decreased by 4.76% from the previous average price target of $15.75.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 4:00 pm